Premium
Chemotherapy with rituximab followed by high‐dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma
Author(s) -
Thieblemont Catherine,
Antal Daciana,
LacotteThierry Laurence,
Delwail Vincent,
Espinouse Daniel,
Michallet AnneSophie,
Traulle Catherine,
BouafiaSauvy Fadhela,
Giraud Christine,
Salles Gilles,
Guilhot François,
Coiffier Bertrand
Publication year - 2005
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.21313
Subject(s) - medicine , rituximab , mantle cell lymphoma , transplantation , chemotherapy , autologous stem cell transplantation , surgery , hematopoietic stem cell transplantation , lymphoma , gastroenterology , oncology
BACKGROUND The authors evaluated the efficacy of chemotherapy combined with rituximab followed by high‐dose therapy (HDT) plus autologous stem cell transplantation in patients with mantle cell lymphoma (MCL). METHODS This was a retrospective analysis of 34 patients who were treated in 2 departments of hematology, including 29 patients (85%) who received first‐line treatment. Rituximab was administered as 4 injections just before harvest in 25 patients (73%) or simultaneously with chemotherapy in 9 patients (27%). HDT included total body irradiation in 26 patients (77%). RESULTS After induction therapy, all patients except one reached a response: There were 14 (41%) complete responses (CR) and 19 (56%) partial responses (PR). Stem cell harvest was successful in all patients but 2, with a median number of 5.9 CD34‐positive cells per 10 6 /kg. Three months after transplantation, 24 patients (71%) were in CR, and 7 patients (21%) were in PR. At 3 years from the day of transplantation, the estimated overall survival was 87%. With a median follow‐up at 2.6 years, the estimated median time to disease progression was 3.4 years. Rituximab treatment before harvest did not delay hematopoietic reconstitution: The median time it took patients to recover absolute neutrophil count to > 0.5 G/L was 10 days. CONCLUSIONS Chemotherapy combined with rituximab followed by HDT improved the overall survival and progression‐free survival in patients MCL without adding toxicities. Cancer 2005. © 2005 American Cancer Society.